Supernus Pharm (SUPN) Stock Price, Quote & News

Latest News on SUPN

Mar 4, 2025, 4:30 PM EST - 6 weeks ago

Supernus to Participate in Two Upcoming Investor Conferences

Feb 27, 2025, 8:30 AM EST - 7 weeks ago

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 6:56 PM EST - 7 weeks ago

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:01 PM EST - 7 weeks ago

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 11:33 AM EST - 2 months ago

BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Feb 19, 2025, 10:29 AM EST - 2 months ago

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Feb 18, 2025, 4:25 PM EST - 2 months ago

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Feb 11, 2025, 4:30 PM EST - 2 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 9:00 AM EST - 2 months ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease

Dec 16, 2024, 4:30 PM EST - 4 months ago

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Nov 26, 2024, 5:00 PM EST - 5 months ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 5 months ago

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Nov 12, 2024, 11:57 AM EST - 5 months ago

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 4, 2024, 10:51 PM EST - 5 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:10 PM EDT - 6 months ago

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Oct 21, 2024, 4:25 PM EDT - 6 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Oct 17, 2024, 4:05 PM EDT - 6 months ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Oct 10, 2024, 5:12 PM EDT - 6 months ago

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Sep 24, 2024, 7:30 AM EDT - 7 months ago

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Sep 19, 2024, 4:30 PM EDT - 7 months ago

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 11, 2024, 11:25 PM EDT - 7 months ago

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 11, 2024, 2:38 PM EDT - 7 months ago

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Aug 28, 2024, 4:15 PM EDT - 8 months ago

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 19, 2024, 7:00 AM EDT - 8 months ago

Market Cap	1.72B
Revenue (ttm)	661.82M
Net Income (ttm)	73.87M
EPS (ttm)	N/A
PE Ratio	15.99
Forward PE	19.69
Profit Margin	11.16%
Debt to Equity Ratio	0.00

Volume	476,300
Avg Vol	678,188
Day's Range	N/A - N/A
Shares Out	55.81M
Stochastic %K	22%
Beta	0.90
Analysts	Sell
Price Target	$38.80